Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Krystal Biotech in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of $7.65 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $215.00 price target on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million.
Several other research firms have also recently issued reports on KRYS. Guggenheim decreased their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 6th. Citigroup cut their price target on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a report on Friday, May 16th. Jefferies Financial Group started coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and a consensus target price of $211.13.
Read Our Latest Stock Report on KRYS
Krystal Biotech Stock Performance
Krystal Biotech stock traded down $3.26 during midday trading on Tuesday, reaching $137.07. 295,086 shares of the company were exchanged, compared to its average volume of 304,820. The firm's 50-day simple moving average is $146.57 and its 200-day simple moving average is $161.50. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $219.34. The company has a market capitalization of $3.96 billion, a price-to-earnings ratio of 45.84 and a beta of 0.65.
Institutional Trading of Krystal Biotech
Institutional investors and hedge funds have recently made changes to their positions in the company. Entropy Technologies LP purchased a new stake in Krystal Biotech during the fourth quarter valued at about $548,000. Principal Financial Group Inc. lifted its stake in shares of Krystal Biotech by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock valued at $19,340,000 after purchasing an additional 3,727 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Krystal Biotech by 27.3% during the 4th quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock worth $1,000,000 after purchasing an additional 1,369 shares during the period. Raymond James Financial Inc. acquired a new stake in Krystal Biotech during the 4th quarter worth approximately $15,989,000. Finally, JPMorgan Chase & Co. raised its holdings in Krystal Biotech by 18.7% in the fourth quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock valued at $23,786,000 after buying an additional 23,934 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
See Also
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
